



## **First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted**

April 25, 2022 09:30 AM Eastern Daylight Time

NEW YORK & LONDON & PARIS--([BUSINESS WIRE](#))--Regulatory News:

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office ("US PTO") has granted the patent regarding the Rapid Pathogen Infectious Disease Liquid Biopsy Diagnostics ("RPIDD") regarding the invention of an unbiased and simultaneous amplification method for DNA library preparation (US Patent No : US11,280,028 B1) to A\*STAR institution, a Singapore based institution with whom Aptorum has an exclusive licensing agreement of the said technology. The RPIDD technology has been exclusively licensed by Aptorum from A\*Star through its subsidiary, Aptorum Innovations Holding Pte Limited.

The RPIDD invention employs a unique method in preparing DNA libraries from samples which contain more than one type of nucleic acids in substantially low amount comparative to non-nucleic acid molecules in the sample within a remarkably shorter turnaround time and substantially more simplified steps compared to conventional methods of preparing DNA library.

Mr. Darren Lui, President and Executive Director of Aptorum Group Limited comments "Through our collaboration partner A\*STAR, we are extremely delighted that the USPTO has recognised the uniqueness of our RPIDD technology and hence granted the said patent. The patented RPIDD method is going to revolutionize the traditional first line clinical diagnostics for infectious diseases such as blood culture, PCR (etc), and we are convinced that a rapid molecular liquid biopsy based diagnostics approach for infectious diseases will disrupt the current approaches and hence in due course potentially reduce infected patient's mortality and morbidity. We are now spearheading the efforts in the ongoing clinical validation and pre-commercialisation preparation of our patented RPIDD."

### **About Aptorum's Rapid Pathogen Identification and Detection Diagnostics Technology (RPIDD)**

RPIDD is an innovative liquid biopsy-driven rapid pathogen molecular diagnostics technology. Proprietary technologies are being developed to enrich pathogenic DNA / RNA for analysis through harnessing the power of Next-Generation Sequencing platforms and proprietary artificial intelligence-based software analytics with the goal to rapidly identify and detect any foreign pathogens (virus, bacteria, fungus, parasites) without bias through its genome composition and to identify other unknown pathogens and novel mutated pathogens. RPIDD has been and continues to be validated in human samples and so far, such testing has been able to detect pathogens – ranging from bacteria, fungi and viruses in an unbiased manner. RPIDD is currently under validation in-human.

### **About Aptorum Group Limited**

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.

For more information about Aptorum Group, please visit [www.aptorumgroup.com](http://www.aptorumgroup.com).

## **Disclaimer and Forward-Looking Statements**

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein.

Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release is provided "as is" without any representation or warranty of any kind.

## **Contacts**

**Aptorum Group Limited**

**Investor Relations Department**

**[investor.relations@aptorumgroup.com](mailto:investor.relations@aptorumgroup.com)**

**+44 20 80929299**

**Redchip – Financial Communications United States**

**Investor relations**

**Dave Gentry**

**[dave@redchip.com](mailto:dave@redchip.com)**

**+1 407 491 4498**

**Actifin – Financial Communications Europe**

Investor relations

Ghislaine Gasparetto

[ggasparetto@actifin.fr](mailto:ggasparetto@actifin.fr)

+33 1 56 88 11 22

## #Hashtags

[#infectiousdisease](#)

[#novel](#)

[#nasdaq](#)

[#drugdevelopment](#)

[#orphandrug](#)

[#biopharmaceutical](#)

[#liquidbiopsy](#)

[#clinical](#)

[#euronext](#)

[#smallmolecule](#)